ArticleJournal of clinical microbiology1993
Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies.
Article in Journal of clinical microbiology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- Article
- Article
- Actin-Dependent Nonlytic Rotavirus Exit and Infectious Virus Morphogenetic Pathway in Nonpolarized Cells.Journal of virology · 2018Article
- Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.Journal of virology · 2015Article
- Mutations in the rotavirus spike protein VP4 reduce trypsin sensitivity but not viral spread.The Journal of general virology · 2013Article
- Cross-linking of rotavirus outer capsid protein VP7 by antibodies or disulfides inhibits viral entry.Journal of virology · 2011Article
- Rhesus rotavirus entry into a polarized epithelium is endocytosis dependent and involves sequential VP4 conformational changes.Journal of virology · 2011Article
- Effect of mutations in VP5 hydrophobic loops on rotavirus cell entry.Journal of virology · 2010Article
- A rotavirus spike protein conformational intermediate binds lipid bilayers.Journal of virology · 2010Article
- VP5* rearranges when rotavirus uncoats.Journal of virology · 2009Article
- Analysis of the kinetics of transcription and replication of the rotavirus genome by RNA interference.Journal of virology · 2009Article
- A longitudinal cohort study in calves evaluated for rotavirus infections from 1 to 12 months of age by sequential serological assays.Archives of virology · 2009Article
- Defective rotavirus particle assembly in lovastatin-treated MA104 cells.Archives of virology · 2008Article
- Assembly of highly infectious rotavirus particles recoated with recombinant outer capsid proteins.Journal of virology · 2006Article
- Dissecting rotavirus particle-raft interaction with small interfering RNAs: insights into rotavirus transit through the secretory pathway.Journal of virology · 2006Article
- High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain.Journal of virology · 2006Article
- Silencing the morphogenesis of rotavirus.Journal of virology · 2005Article
- Rotavirus diarrhea severity is related to the VP4 type in Mexican children.Journal of clinical microbiology · 2003Article
- Interaction of rotaviruses with Hsc70 during cell entry is mediated by VP5.Journal of virology · 2003Article
- Proteolysis of monomeric recombinant rotavirus VP4 yields an oligomeric VP5* core.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Three human rotavirus (HRV) VP4 serotypes and one subtype have been described on the basis of a fourfold or an eightfold-or-greater difference in neutralization titer when tested with hyperimmune antisera to recombinant VP4 or VP8* (serotypes P1A, P1B, P2, and P3). To start to analyze the antigenic basis underlying serotype specificity, we produced a library of 13 VP4-specific neutralizing monoclonal antibodies (NMAbs) to two HRVs, the serotype P1A strain Wa and the serotype P2 strain ST3, and characterized the reactivity of these NMAbs with a panel of serotypically diverse HRV strains by neutralization assay and enzyme-linked immunosorbent assay (ELISA). We characterized the serotypic specificity of the NMAbs by using a fourfold or an eightfold-or-greater difference in titer against the homologous (i.e., immunogen) and heterologous strains as a criterion for serotype. Some ST3-derived NMAbs reacted specifically with serotype P2 HRVs by ELISA and/or neutralization assay, while some Wa-derived NMAbs reacted specifically by ELISA and/or neutralization assay with some or all serotype P1A HRVs. Other Wa- and ST3-derived NMAbs reacted with some or all serotype P1A and P2 HRV strains by neutralization assay and ELISA. Most NMAbs did not react with serotype P1B or P3 strains. In previous studies, three distinct operationally defined epitopes have been identified on VP4 by examining the reactivity patterns of selected antigenic variants of HRV strain KU. At least one of the NMAbs described here recognizes an epitope unrelated to these previously identified epitopes, since it neutralized both KU and its variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.